ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 68 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $258 | – | 46 | – | 0.00% | – |
| Q2 2021 | $0 | – | 0 | – | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q1 2019 | $3,000 | +200.0% | 500 | +13.6% | 0.00% | – |
| Q4 2018 | $1,000 | -75.0% | 440 | 0.0% | 0.00% | – |
| Q3 2018 | $4,000 | 0.0% | 440 | 0.0% | 0.00% | – |
| Q2 2018 | $4,000 | -42.9% | 440 | -25.4% | 0.00% | – |
| Q1 2018 | $7,000 | 0.0% | 590 | 0.0% | 0.00% | – |
| Q4 2017 | $7,000 | +16.7% | 590 | -14.5% | 0.00% | – |
| Q3 2017 | $6,000 | -68.4% | 690 | -37.6% | 0.00% | -100.0% |
| Q2 2017 | $19,000 | +72.7% | 1,105 | +104.6% | 0.00% | – |
| Q1 2017 | $11,000 | -82.0% | 540 | -86.2% | 0.00% | -100.0% |
| Q4 2016 | $61,000 | +144.0% | 3,900 | +105.3% | 0.00% | +200.0% |
| Q3 2016 | $25,000 | +525.0% | 1,900 | +216.7% | 0.00% | – |
| Q2 2016 | $4,000 | +33.3% | 600 | +20.0% | 0.00% | – |
| Q1 2016 | $3,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |